Warpspeed — Mission
warpspeed.sh · 1,126 words · saved by 1 readers
Clinical trial forecasts powered by Monte Carlo simulation
March 30, 2026 We used AI to predict the failure of a Phase III trial before the results were announced. Today, we're publishing ten more predictions for the future. In 2023, Gossamer Bio decided to advance its pulmonary hypertension drug to a Phase III trial. The drug had performed poorly in a prior Phase II1, but the company noticed exceptionally strong efficacy in a small patient subgroup with very severe disease. They decided to run a Phase III trial focused mostly on these very severe patients. On February 20, 2026, Gossamer announced a statistical failure of the trial and its stock…
saved by
related reading
- Warpspeed — Forecastswarpspeed.sh
- Dario Amodei — Machines of Loving Gracedarioamodei.com
- Dario Amodei — Machines of Loving Gracedarioamodei.com
- What will it take for AI to change drug discovery?writingruxandrabio.com
- Intelligence is not the main bottleneck - by Ruxandra Teslowritingruxandrabio.com
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Why is progress in biology so slow?sam-rodriques.com
- Clinic-in-the-Loopasimov.press
- AI Versus Eroom's Lawsubstack.com
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- Dario Amodei — Machines of Loving Gracedarioamodei.com
- The Humanity Projectsam-rodriques.com